Articles that tag ALEC but are mainly about other companies.
Developing Latozinemab (AL001) for frontotemporal dementia and AL101 (GSK4527226) for early Alzheimer's. The company completed Phase II enrollment in April 2025 and has advanced with key regulatory designations, addressing unmet needs in non-Alzheimer's dementia subtypes.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
